TriLink BioTechnologies®, a division of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ), announced a non-exclusive ...

Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

Downstream processing for mRNA manufacturing is currently too complex, but simplifying by using precipitation looks promising.

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The ...

The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

In a precedential decision issued June 4, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a district ...

In this week’s edition of InnovationRx, we look at the impact of Trump’s proposed budget cuts on biomedical research and ...

Moderna had already started a Phase 1/2 trial of its bird flu (H5N1) vaccine and reported strong early results.

HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

American researchers have now found a news type of mRNA vaccine to prevent the deadly disease. A team of US researchers have found that the vaccine is more scalable and adaptable to tackle ...